Results 321 to 330 of about 22,609,350 (346)

CTLA-4 can function as a negative regulator of T cell activation.

Immunity, 1994
T. L. Walunas, D. Lenschow, C. Y. Bakker, P. Linsley, G. Freeman, J. Green, Craig B. Thompson, Craig B. Thompson, J. Bluestone   +8 more
semanticscholar   +1 more source

CTLA-4

2013
Tasha Hughes, Howard L. Kaufman
openaire   +1 more source

CTLA-4

1998
Tak W. Mak, Josef Penninger, John Roder, Janet Rossant, Mary Saunders   +4 more
openaire   +1 more source

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

Nature Reviews Clinical Oncology, 2016
C. Boutros, A. Tarhini, É. Routier, O. Lambotte, F. Ladurie, F. Carbonnel, Hassane Izzeddine, A. Marabelle, S. Champiat, A. Berdelou, E. Lanoy, M. Texier, C. Libenciuc, A. Eggermont, J. Soria, C. Mateus, C. Robert   +16 more
semanticscholar   +1 more source

Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade

Cell, 2018
Sachet A Shukla, Pavan Bachireddy, Bastian Schilling   +2 more
exaly  

CTLA-4

2006
openaire   +1 more source

PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways

Immunity, 2019
Yunlong Zhao, Xiaozheng Xu, Zhe Huang
exaly  

CTLA-4

2011
openaire   +1 more source

CTLA-4

2014
openaire   +1 more source

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy

Cell Research, 2018
Fei Tang, Mingyue Liu, Juanjuan Su
exaly